Buchumschlag

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Charly Gaul, Sónia Ferreira, Troels Johansen
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Headache: The Journal of Head and Face Pain
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
von: Koichi Ikeda, et al.
Veröffentlicht: (2025)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
von: Nathaniel M. Schuster, et al.
Veröffentlicht: (2025)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
von: Muneto Tatsumoto, et al.
Veröffentlicht: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
von: Graham A. McLeod, et al.
Veröffentlicht: (2025)

Afterimage duration differs for migraine with or without aura
von: Florian Rimmele, et al.
Veröffentlicht: (2025)

The impact of fear of attacks on pain‐related disability in cluster headache: Insights from the fear avoidance model
von: Janosch Fox, et al.
Veröffentlicht: (2024)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
von: Janosch Fox, et al.
Veröffentlicht: (2025)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Veröffentlicht: (2025)

Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive
von: Louise O'Hare, et al.
Veröffentlicht: (2025)

A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine ( TEAM) study
von: Gregory A. Panza, et al.
Veröffentlicht: (2024)

The cortical spreading depression/migraine aura hypothesis – Finally some definitive evidence
von: Andrew C. Charles, et al.
Veröffentlicht: (2025)

Beyond aura: Understanding migraine as a cycling pan‐sensory threshold disease
von: Arne May
Veröffentlicht: (2024)

The PATCH trial: 5% lidocaine‐medicated plaster for trigeminal neuralgia—Results of a multicentric, enriched enrollment, randomized withdrawal, double‐blind, vehicle‐controlled, parallel‐group study
von: Chunmei Zhao, et al.
Veröffentlicht: (2024)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
von: Jeffrey D. Sharon, et al.
Veröffentlicht: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
von: Delora E. Denney, et al.
Veröffentlicht: (2024)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
von: Serena Laura Orr, et al.
Veröffentlicht: (2024)

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
von: Ghader Mohammadnezhad, et al.
Veröffentlicht: (2024)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
von: Stephen Silberstein, et al.
Veröffentlicht: (2026)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
von: Susan Hutchinson, et al.
Veröffentlicht: (2026)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
von: Geneviève Tourigny‐Ruel, et al.
Veröffentlicht: (2026)

Insomnia severity in migraine: The role of headache frequency, aura status, and comorbidities—A cross‐sectional study
von: Kuang‐Heng Lee, et al.
Veröffentlicht: (2025)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
von: Emmanuelle A. D. Schindler, et al.
Veröffentlicht: (2025)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
von: Stephen D. Silberstein, et al.
Veröffentlicht: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
von: Larry Charleston, et al.
Veröffentlicht: (2026)

Heavy metal and trace element alterations in patients during a migraine attack
von: Sevilay Vural, et al.
Veröffentlicht: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
von: Anna Gryglas‐Dworak, et al.
Veröffentlicht: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
von: Rikki Mangrum, et al.
Veröffentlicht: (2024)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
von: Andrew Blumenfeld, et al.
Veröffentlicht: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
von: Jennifer Robblee, et al.
Veröffentlicht: (2024)

Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study
von: Richard J. Bertz, et al.
Veröffentlicht: (2024)

Integrating gepants into clinical practice for the acute treatment of migraine
von: Richard B. Lipton, et al.
Veröffentlicht: (2026)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
von: Yunus Emre Meydanal, et al.
Veröffentlicht: (2025)

Preserved working memory performance along with subcortical modulation during peri‐ictal phases in spontaneous migraine attacks
von: Amparo Ruiz‐Tagle, et al.
Veröffentlicht: (2024)

Microneedles for the treatment of migraine and orofacial pain: A narrative review
von: Baicheng Cao, et al.
Veröffentlicht: (2026)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
von: Gerlinde Freimark, et al.
Veröffentlicht: (2025)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
von: Chia‐Chun Chiang, et al.
Veröffentlicht: (2024)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
von: Richard B. Lipton, et al.
Veröffentlicht: (2025)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
von: Stephanie J. Nahas, et al.
Veröffentlicht: (2025)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
von: Christoph T. Berger, et al.
Veröffentlicht: (2026)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
von: Jessica Ailani, et al.
Veröffentlicht: (2024)